JMP Securities lowered the firm’s price target on Aura Biosciences to $19 from $21 and keeps an Outperform rating on the shares. Aura will kick off its pivotal CoMpass study in choroidal melanoma this quarter with data from earlier pipeline opportunities coming next year, the analyst tells investors in a research note. Earlier this week, Aura presented 12-month Phase 2 data at AAO earlier this week showing bel-sar has durable tumor control and vision preservation, which the firm views as derisking for thePhase 3 CoMpass trial, which has a SPA and is slated to start dosing patients this quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AURA:
- Insider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16M
- Aura Biosciences reports Q3 EPS (48c), consensus (52c)
- Aura Biosciences price target lowered to $20 from $23 at Scotiabank
- Aura Biosciences 11M share Spot Secondary priced at $9.00
- Aura Biosciences announces common stock offering, no amount given
